Literature DB >> 19501221

Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system.

Maria M Hidalgo1, Creusa Hidalgo-Regina, M Valeria Bahamondes, Ilza Monteiro, Carlos A Petta, Luis Bahamondes.   

Abstract

BACKGROUND: The levonorgestrel-releasing intrauterine system (LNG-IUS) is a contraceptive method approved for five years of use. However, there is some evidence that its life span may be longer. The aim of the study was to evaluate serum levonorgestrel (LNG) and estradiol (E(2)) levels and endometrial thickness every 6 months from 7 to 8 1/2 years after insertion. STUDY
DESIGN: At the end of the approved 5-year life span, no replacement devices were available; therefore, 86 women were allowed to retain the same device for a further 2 years. At the 7-year follow-up visit, the women who consented were again allowed to retain the same device for a further 18 months and were followed-up at six-monthly intervals. At each visit, vaginal sonography was performed to measure endometrial thickness, and a blood sample was taken to measure LNG and E(2).
RESULTS: Eighty-four months after insertion, 67 women aged 34.3+/-0.8 years (mean+/-SEM) (range, 25-49 years) returned for follow-up. Mean+/-SEM LNG levels decreased from an initial 253+/-27 pg/mL (range, 86-760) during the first 2 months following insertion to 137+/-12 (range, 23-393) at 84 months and 119+/-9 pg/mL (range, 110-129) at 102 months of use (+/-SEM). At 84 months of use, mean+/-SEM endometrial thickness was 2.8+/-0.1 mm, increasing to 3.8+/-0.5 mm at 102 months of use. The incidence of amenorrhea decreased from 41.8% at 84 months to 31.5% at 102 months of use. No correlation was found between LNG levels and bleeding patterns; however, a weak correlation was found between high body mass index (kg/m(2)), high weight, and low serum LNG levels. E(2) levels were similar to those of the follicular phase of the menstrual cycle of regularly menstruating women.
CONCLUSIONS: During extended use of the LNG-IUS, serum LNG levels were nearly half those found in the first 2 months of use (Wilcoxon signed rank test); serum E(2) levels were normal. Despite the very thin endometrium, menstrual bleeding was reinstated in many cases. At the end of its 5-year life span, there is a window for changing the LNG-IUS, and physicians and users should not be concerned about delaying replacement of the device for a short time beyond the approved life span; however, maintaining the same device long after its approved life span cannot be recommended.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19501221     DOI: 10.1016/j.contraception.2009.01.004

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  13 in total

Review 1.  Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.

Authors:  Janet P Hapgood; Charu Kaushic; Zdenek Hel
Journal:  Endocr Rev       Date:  2018-02-01       Impact factor: 19.871

2.  CCR5 Expression Levels in HIV-Uninfected Women Receiving Hormonal Contraception.

Authors:  Gaia Sciaranghella; Cuiwei Wang; Haihong Hu; Kathryn Anastos; Zaher Merhi; Marek Nowicki; Frank Z Stanczyk; Ruth M Greenblatt; Mardge Cohen; Elizabeth T Golub; D Heather Watts; Galit Alter; Mary A Young; Athe M N Tsibris
Journal:  J Infect Dis       Date:  2015-04-20       Impact factor: 5.226

3.  Pharmacokinetics of Hormonal Contraception in Individuals with Obesity: a Review.

Authors:  Shaalini Ramanadhan; William J Jusko; Alison Edelman
Journal:  Curr Obstet Gynecol Rep       Date:  2020-05-04

4.  Association of baseline bleeding pattern on amenorrhea with levonorgestrel intrauterine system use.

Authors:  Manuela Mejia; Colleen McNicholas; Tessa Madden; Jeffrey F Peipert
Journal:  Contraception       Date:  2016-06-27       Impact factor: 3.375

Review 5.  Clarification of contraceptive drug pharmacokinetics in obesity.

Authors:  William J Jusko
Journal:  Contraception       Date:  2016-08-16       Impact factor: 3.375

6.  Reciprocal Modulation of Antiretroviral Drug and Steroid Receptor Function In Vitro.

Authors:  Sigcinile Dlamini; Michael Kuipa; Kim Enfield; Salndave Skosana; John G Woodland; Johnson Mosoko Moliki; Alexis J Bick; Zephne van der Spuy; Michelle F Maritz; Chanel Avenant; Janet P Hapgood
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

7.  Non-contraceptive applications of the levonorgestrel intrauterine system.

Authors:  Maria Isabel Rodriguez; Philip D Darney
Journal:  Int J Womens Health       Date:  2010-08-09

Review 8.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400

9.  Levonorgestrel intrauterine system (Mirena): An emerging tool for conservative treatment of abnormal uterine bleeding.

Authors:  Pallavi C Dhamangaonkar; K Anuradha; Archana Saxena
Journal:  J Midlife Health       Date:  2015 Jan-Mar

Review 10.  Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies.

Authors:  Andrea Ries Thurman; Meredith R Clark; Jennifer A Hurlburt; Gustavo F Doncel
Journal:  Int J Womens Health       Date:  2013-10-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.